# reload+after+2024-01-20 03:46:05.312887
address1§Semmelweisstrasse 7
city§Planegg
zip§82152
country§Germany
phone§49 89 89927 0
fax§49 89 89927 222
website§https://www.morphosys.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule to treat myelofibrosis; Felzartamab, an antibody directed against CD38 for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule to promote anti-tumor activity by inhibiting EZH2 and EZH1. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases; and Otilimab, an antibody for rheumatoid arthritis. The company has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.
fullTimeEmployees§544
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Jean-Paul  Kress M.D.', 'age': 58, 'title': 'Chairman of Management Board, MD & CEO', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 2219905, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Lucinda  Crabtree Ph.D.', 'age': 44, 'title': 'CFO & Member of Management Board', 'yearBorn': 1979, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Charlotte  Lohmann', 'age': 53, 'title': 'Chief Legal and Human Resources Officer & Member of Management Board', 'yearBorn': 1970, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Klaus  De Wall', 'title': 'Head of Accounting & Tax', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Margit  Urban', 'title': 'Head of Discovery Alliances & Technologies', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Julia  Neugebauer Ph.D.', 'title': 'Head of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Barbara  Krebs-Pohl Ph.D.', 'title': 'Chief Business Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Günter  Wellnhofer', 'title': 'Head of Technical Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Ralf  Ostendorp', 'title': 'Head of Protein Sciences & CMC', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Harald  Watzka', 'title': 'Head of Alliance Management', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§2
boardRisk§1
compensationRisk§6
shareHolderRightsRisk§1
overallRisk§1
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.569
priceToSalesTrailing12Months§5.562945
currency§USD
dateShortInterest§1702598400
forwardEps§-1.71
exchange§NMS
quoteType§EQUITY
shortName§MorphoSys AG
longName§MorphoSys AG
firstTradeDateEpochUtc§1524144600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§e69ac107-9473-3ee4-815d-c7bb67c1cad3
gmtOffSetMilliseconds§-18000000
targetHighPrice§17.06
targetLowPrice§4.77
targetMeanPrice§12.03
targetMedianPrice§13.15
recommendationMean§2.2
recommendationKey§buy
numberOfAnalystOpinions§4
quickRatio§2.751
grossMargins§0.79042
ebitdaMargins§-0.83536005
trailingPegRatio§None
